|会社名||Otonomy Inc （オトノミ―）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 オトノミ(Otonomy Inc.)はバイオ医薬品会社である。同社は耳疾患・障害の治療薬の開発・製品化に従事する。同社の製品候補には、OTIPRIO、OTO-104、OTO-311がある。 OTIPRIOは、医師が投与する単回用量の抗菌剤であり、鼓膜瘻造設術（TTP）手術を受けた輸液による両側性中耳炎の小児患者の治療に使用され、商業的に購入することができる。OTO-104は、メニエール病および他の内耳状態の治療用の開発中のステロイドデキサメタゾンの持続曝露製剤である。OTO-311は、耳鳴りの治療用の開発中のN-メチル-D-アスパラギン酸（NMDA）受容体拮抗薬ガシクリジンの持続曝露製剤である。また、年齢関連の難聴（老人性難聴）などの感音難聴を対象とした他の多様な製品候補を有する。 オトノミ―は、米国の臨床段階のバイオ医薬品企業。耳の疾患および障害のための治療薬の開発と商業化に焦点を当てる。｢AurionPro｣は、鼓膜切開チュ―ブの配置手術時に中耳滲出の小児患者のための抗生物質シプロフロキサシン製剤､｢OTO-104｣は、メニエ―ル病患者の治療のためにステロイド・デキサメタゾンの製剤などを提供する。 Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.|
|本社所在地||4796 Executive Drive San Diego CA 92121 USA|
|代表者氏名||Jay Lichter ジェイ・ライヒター|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Otonomy Inc revenues decreased 38% to $424K. Net loss decreased 50% to $25M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative - other decrease of 65% to $7M (expense) Research and developme decrease of 51% to $11.5M (expense) Interest income increase of 24% to $763K (income).|
Otonomy Inc. (NASDAQ: OTIC) Continues To Thrive In 2022, As Its Stock Is Down -82.21% Year-To-Date 2022/08/04 13:30:00 Marketing Sentinel
During the last session, Otonomy Inc. (NASDAQ:OTIC)’s traded shares were 26.85 million, with the beta value of the company hitting 1.37. At the end of the trading day, the stock’s price was $0.37, reflecting an intraday gain of 48.42% or $0.12. The 52-week high for the OTIC share is $2.59, that puts it down -600.0 … Otonomy Inc. (NASDAQ: OTIC) Continues To Thrive In 2022, As Its Stock Is Down -82.21% Year-To-Date Read More »
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday 2022/08/04 09:54:33 Benzinga
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX ) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. ECMOHO Limited (NASDAQ: MOHO ) jumped 146.1% to settle at $0.4085 on above-average volume. Helius Medical Technologies, Inc. (NASDAQ: HSDT ) shares climbed 145.3% to close at $1.58 on Wednesday after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN ) jumped 140.3% to close at $6.20. Enveric Biosciences, Inc. (NASDAQ: ENVB ) gained 106% to settle at $13.10. Enveric Biosciences recently announced an $8 million registered direct offering and private placement. Heart Test Laboratories, Inc. (NASDAQ: HSCS ) jumped 89.6% to close at $3.28. Poseida Therapeutics, Inc. (NASDAQ: PSTX ) shares surged 85.6% to close at $4.51 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Eargo, Inc. (NASDAQ: EAR ) shares gained 75.6% to settle at $1.23.
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday''s Mid-Day Session 2022/08/03 16:59:27 Benzinga
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT ) shares jumped 167% to $1.72 after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN ) gained 112.4% to $5.48. Eargo, Inc. (NASDAQ: EAR ) shares climbed 102.8% to $1.42. The company is scheduled to report Q2 earnings on Monday, August 8. Poseida Therapeutics, Inc. (NASDAQ: PSTX ) shares jumped 99.6% to $4.85 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Applied DNA Sciences, Inc. (NASDAQ: APDN ) climbed 75.7% to $4.92 on continued strength after the company initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. Kintara Therapeutics, Inc. (NASDAQ: KTRA ) gained 70% to $0.3013 after the company entered into an equity purchase agreement with Lincoln Park Capital for up to $20 million. Ping Identity Holding Corp. (NYSE: PING ) shares climbed 59.8% to $27.92 after the company announced it will be acquired by Thoma Bravo for $28.50 per share in cash.
Should Value Hunters Buy Otonomy Inc. (NASDAQ: OTIC) Stock? 2022/08/03 14:30:00 Stocks Register
The trading price of Otonomy Inc. (NASDAQ:OTIC) closed lower on Tuesday, August 02, closing at $0.25, -14.42% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.24 and $0.2798. In examining the 52-week price action we see that the stock hit a 52-week high … Should Value Hunters Buy Otonomy Inc. (NASDAQ: OTIC) Stock? Read More »
Delighting stocks: Otonomy, Inc. (NASDAQ:OTIC -15.28%), B2Gold Corp. (AMEX:BTG -1.43%) 2022/08/03 00:07:59 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Delighting stocks: Otonomy, Inc. (NASDAQ:OTIC -15.28%), B2Gold Corp. (AMEX:BTG -1.43%) appeared first on Stocks Equity .
Otonomy Inc.s (OTIC) $2.00: At This Price, Its Worthwhile 2021/12/04 14:00:00 Stocks Register
Otonomy Inc. (NASDAQ:OTIC) concluded the trading at $2.00 on Friday, December 03 with a fall of -3.38% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.07 and 5Y monthly beta was reading 2.01 with its price kept floating in the range Otonomy Inc.s (OTIC) $2.00: At This Price, Its Worthwhile Read More »
Geode Capital Management LLC Has $953,000 Stock Position in Otonomy, Inc. (NASDAQ:OTIC) 2021/11/23 09:06:45 Transcript Daily
Geode Capital Management LLC increased its stake in shares of Otonomy, Inc. (NASDAQ:OTIC) by 2.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 427,394 shares of the biopharmaceutical company’s stock after buying an additional 11,204 shares during the period. […]
Otonomy (NASDAQ:OTIC) Lowered to Sell at Zacks Investment Research 2021/11/17 08:44:41 Dakota Financial News
Zacks Investment Research downgraded shares of Otonomy (NASDAQ:OTIC) from a hold rating to a sell rating in a report published on Tuesday, Zacks.com reports. According to Zacks, Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. 
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference 2021/11/16 12:30:00 Intrado Digital Media
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will participate in a pre-recorded company fireside chat, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021.
Cantor Fitzgerald Reaffirms Overweight Rating for Otonomy (NASDAQ:OTIC) 2021/11/13 15:12:43 Dakota Financial News
Otonomy (NASDAQ:OTIC)s stock had its overweight rating reaffirmed by Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Zacks.com reports. Separately, Zacks Investment Research cut Otonomy from a buy rating to a hold rating in a research report on Thursday, October 7th. OTIC opened at $2.25 on Thursday. The company has 
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update 2021/11/10 21:18:00 Intrado Digital Media
Conference call and webcast today at 4:30 p.m. ET
Zacks: Analysts Anticipate Otonomy, Inc. (NASDAQ:OTIC) Will Post Quarterly Sales of $70,000.00 2021/11/07 10:04:41 Dakota Financial News
Wall Street analysts forecast that Otonomy, Inc. (NASDAQ:OTIC) will report sales of $70,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Otonomys earnings. The lowest sales estimate is $50,000.00 and the highest is $80,000.00. Otonomy posted sales of $50,000.00 in the same quarter last year, which would indicate a 
Analysts Anticipate Otonomy, Inc. (NASDAQ:OTIC) to Announce -$0.19 EPS 2021/11/05 12:06:41 Dakota Financial News
Brokerages expect Otonomy, Inc. (NASDAQ:OTIC) to announce earnings per share (EPS) of ($0.19) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Otonomy’s earnings, with estimates ranging from ($0.19) to ($0.18). Otonomy posted earnings of ($0.22) per share in the same quarter last year, which indicates a positive year-over-year […]
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting 2021/10/27 11:30:00 Intrado Digital Media
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN). This meeting will be held virtually November 8-11, 2021 with Preview Days taking place November 3-7 during which registered attendees can preview pre-recorded presentations. Otonomys presentations include the previously disclosed positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss, and multiple presentations related to Otonomys preclinical programs.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 オトノミ― OTIC Otonomy Inc.）